Cryptococcal meningitis is a leading cause of death in HIV-infected patients, with an estimated 223,000 cases in 2014 (Rajasingham et al., 2017). The vast majority of infections are due to C. neoformans, and occur in low-income tropical settings. Current international guidelines recommend initial induction treatment with amphotericin combined with flucytosine, followed by consolidation therapy with fluconazole (World Health Organization, 2018). This combination delivers the fastest rates of clearance of yeast from cerebrospinal fluid (CSF) and the best survival rates (Day et al., 2013; Molloy et al., 2018). However, even on this gold standard therapy, 30% of patients will die within 10 weeks of diagnosis (Day et al., 2013; Molloy et al., 2018). Adjunctive therapy with corticosteroids, which has proven beneficial in other forms of meningitis, results in worse outcomes (Beardsley et al., 2016).

Cryptococcal meningitis can also occur in HIV-uninfected patients, including immunocompetent people and those with other causes of immunosuppression. Survival rates are similar to those seen in HIV-infected patients. There are few data from randomized controlled trials to guide treatment in these circumstances. In Vietnam around 20% of cases of cryptococcal meningitis are in HIV-uninfected patients (Chau et al., 2010). Disease is predominantly due to the C. neoformans VNIa-5 lineage; C. gattii is responsible for around 25% of cases (Chau et al., 2010; Ashton et al., 2019; Day et al., 2011; Day et al., 2017).

There has been little progress in development of antifungal drugs for cryptococcal meningitis. Amphotericin and flucytosine are each more than 60 years old; the last novel drug class developed was the azoles, introduced 30 years ago. Access to flucytosine is severely restricted by availability and cost, meaning it is rarely used where disease burden is highest. Despite being off-patent, it has been subject to extraordinary price rises in recent years, with a 2-week course now costs around 30,000 USD in the USA (Merry and Boulware, 2016). Flucytosine is an unattractive prospect for generic manufacturers, because the location of the majority of patients and the few indications outside cryptococcal disease promise only limited financial returns. These same factors hamper the development of novel treatments for cryptococcal disease, and have driven interest in drug re-purposing (Butts et al., 2014; Dolan et al., 2009; Zhai et al., 2012). Re-purposing can be a solution for neglected diseases provided the new indication accounts for only a minority of total prescriptions, and the de facto indications are sufficiently prevalent to ensure availability, price stability, and affordability.

Tamoxifen, a selective estrogen receptor modulator used to treat breast cancer, has anti-cryptococcal activity, appearing to act synergistically when combined with other antifungals against the type strain in vitro, and to be fungicidal when combined with fluconazole in the mouse infection model (Butts et al., 2014; Dolan et al., 2009). We found it to act synergistically with amphotericin against two-thirds of clinical isolates of Cryptococcus neoformans and C. gattii from our archive and to have an additive interaction when combined with fluconazole in vitro (Hai et al., 2019).

Tamoxifen is concentrated in brain tissue (10- to 100-fold compared with plasma) and macrophage phagosomes (a site of growth for Cryptococcus spp.), is off-patent, cheap (~10US cents/tablet) and widely available (Lien et al., 1991a; Lien et al., 1991b). Therefore, it is a promising candidate for the treatment of cryptococcal meningitis. Pharmacokinetic data suggest that doses 5- to 10-fold that used in breast cancer (typically 30 mg/day) should deliver plasma concentrations of tamoxifen greater than the Minimum Inhibitory Concentration 90 (MIC90 16 µg/mL) of Vietnamese clinical isolates (Lien et al., 1991a). Such doses have been used, and well-tolerated, in small cell lung cancer, desmoid tumours, and prostate cancer. These illnesses have comparable or better 1-year survival rates than cryptococcal meningitis (Ngan et al., 2019). While generally well-tolerated, acute side effects that could be detrimental from short-course treatment include QT prolongation of the cardiac de/repolarization cycle, although the risk of life-threatening arrhythmias appears to be low (Grouthier et al., 2018).

In Vietnam induction treatment for cryptococcal meningitis consists of amphotericin combined with fluconazole, consistent with WHO recommendations where flucytosine is unavailable (World Health Organization, 2018). However, this combination is less effective than amphotericin with flucytosine, resulting in slower rates of fungal clearance and worse survival rates (Day et al., 2013; Molloy et al., 2018). The relationship between the rate of fungal clearance from CSF and survival is generally robust; improving the potency of antifungal therapy is likely to be an effective way to reduce deaths (Day et al., 2013; Molloy et al., 2018; Beardsley et al., 2016). The rate of clearance of yeast from CSF associated with an antifungal treatment (the early fungicidal activity, EFA) is a sensitive measure able to detect differences between treatment regimens likely to be associated with survival benefits with far fewer patients than studies powered to survival itself (Brouwer et al., 2004). Small studies powered to this endpoint can serve to filter treatment regimens that can be taken forward in larger trials (Brouwer et al., 2004; Bicanic et al., 2009). We performed an open-label randomised controlled trial to determine whether combining tamoxifen with amphotericin B and fluconazole results in enhanced EFA in HIV infected and uninfected patients with cryptococcal meningitis, and to generate safety data as a prelude to a larger trial powered to mortality (Ngan et al., 2019).

We wanted to determine whether tamoxifen could be repurposed as an affordable treatment for cryptococcal meningitis. Our study was powered to detect an increase in the rate of yeast clearance of at least −0.11 log10 CFU/ml/day when tamoxifen was added to standard of care therapy. Differences of this order of magnitude are associated with improved survival in patients in low-income settings (Day et al., 2013; Molloy et al., 2018; Beardsley et al., 2016). Despite having previously shown that tamoxifen had activity in vitro against historical clinical isolates of C. neoformans, we found its addition had no impact on EFA. Therefore we do not believe that proceeding to a larger trial, powered to survival, is justified.

It is not clear why tamoxifen did not provide benefit in our patients. The susceptibilities of the Cryptococcus isolates from this study to tamoxifen, fluconazole, and amphotericin, were similar to those of isolates from our previous clinical trials (Hai et al., 2019; O'Connor et al., 2020). However, in contrast with our previous findings we found evidence of synergy when tamoxifen was combined with amphotericin in only 12% (95CI 5%, 24%) of isolates from the trial. This compares with the rate in archived isolates of 67% (95CI 47%, 81%) (Hai et al., 2019). Synergy has been suggested as an explanation for the superiority of the amphotericin-flucytosine combination which has delivered improved yeast clearance and survival in a number of trials (Schwarz et al., 2003). In this study, we lack sufficient numbers of isolates where tamoxifen-amphotericin synergy is seen to be able to determine whether synergy per se influences EFA.

A second potential explanation is that we may have failed to attain sufficient concentrations of tamoxifen in our patients. We chose a dose of 300 mg/day, based upon the MIC90 of tamoxifen against our historical isolates (16 mg/L) and the expected plasma concentrations this would achieve. Given that tamoxifen is concentrated in the brain (10- to 100-fold), and in macrophage phagosomes, we consider it unlikely that we did not reach drug concentrations greater than the MIC90 at the disease site, although it is possible that absorption of orally administered drug was impaired in our patients.

The rates of adverse events in our study were similar between patients receiving tamoxifen and those in the control arm. Our study was powered to detect a difference in the rate of clearance of yeast from CSF and therefore may have lacked power to detect differences in rates of rarer adverse events. However, there was greater prolongation of the QTc interval in patients on tamoxifen. The mechanism through which tamoxifen causes QT interval prolongation in humans is unknown. In animals there is evidence that the block is multi-channel, due to both inhibition of the I_KR and I_Ca channels (Asp et al., 2013; He et al., 2003; Liu et al., 1998). Such multi-channel block is considered to confer a reduced risk of life-threatening arrhythmias compared with drugs that block single ion channels. While we did not have any cases of ventricular tachycardia in our study, there was an episode of cardiac arrest in the tamoxifen arm. There are multiple potential causes of cardiac arrest in patients with cryptococcal meningitis, including intracranial pathology and electrolyte disturbances. The cardiac arrest in our study occurred on day 21, 1 week after administration of tamoxifen had finished. However, given tamoxifen’s half-life of 5 to 7 days, and the doses used, it is possible that this event was related. Fluconazole is also a recognised cause of QT prolongation. Here, the mechanism is believed to be through modulation of the I_kr current of the cardiac depolarization cycle (Han et al., 2011). However, we found little evidence of significant QT prolongation in patients in the control arm of our study, and in fact the acute effect of administration of fluconazole was shortening of the QTc interval.

Our experience with tamoxifen is similar to that reported with the anti-depressant drug sertraline. Sertraline has in vitro fungicidal activity against Cryptococcus neoformans and a synergistic effect when combined with fluconazole. Results from a pilot dose-finding study of adjunctive sertraline for cryptococcal meningitis suggested it was a safe and potentially effective treatment, although no contemporaneous controls were enrolled in the trial (Rhein et al., 2016). Subsequently a large randomized controlled trial powered to mortality was stopped due to futility having enrolled 460 patients (Rhein et al., 2019). There was no difference in survival or EFA between the standard therapy or sertraline boosted treatment arms. Of note, a small randomized placebo controled trial from Mexico, published after the phase three trial had begun, found no difference in EFA when sertraline was added to amphotericin and fluconazole, although only 12 patients were enrolled and formal statistical testing was not performed (Villanueva-Lozano et al., 2018). However, it lends further support for the screening of antifungal treatments in small scale studies using this endpoint.

Other drugs suggested as repurposing candidates for cryptococcal meningitis include the calcium antagonists, such as nifedipine and its sister drugs, used to treat hypertension, and flubendazole, an antihelminthic (Truong et al., 2018). Flubendazole is perhaps the most promising of these, appearing to be more potent in vitro than fluconazole, and active against Cryptococcus isolates across a range of fluconazole susceptibilities. It crosses the blood brain barrier in mice, but data are lacking regarding humans (Fok and Kassai, 1998). While nifedipine crosses the blood brain barrier, it seems unlikley that normal doses and oral administration would reach the plasma levels needed to inhibit Cryptococcus growth. However, given our experiences with tamoxifen, and those of others with sertraline, we would caution that better laboratory screening methods than those currently in use are needed to identify potential new treatments for cryptococcal meningitis.

In the mean time, improving access to flucytosine remains a key goal. Progress has been made through efforst to increase generic manufacture through the the Unitaid- Clinton Health Access Initiative for Advanced HIV Disease Initiative’s partnership with the Global Fund and the President's Emergency Plan for AIDS Relief. This has resulted in price reductions allowing 2-week treatment courses to be procured for around $100 in some locations.

This appendix has been provided by the authors to give readers additional information about their work.

data{
//for longitudinal data
int<lower=1> N_long; // no. rows
int<lower=0,upper=1> y2_censInd[N_long]; // under detection limit index
int<lower=1> I; // no. patient
int<lower=1,upper=I> patid[N_long]; //patid index for random effect
vector [N_long]time_scale; // time_scale censoring data
real log10fc_obs[N_long];// log10fc observing data
real <upper=log10(5)>C;
int<lower=1> p_X;
int<lower=1> p_X_intercept;
int<lower=1> p_X_slope;
vector[p_X]mean_X;
vector<lower=0>[p_X]sd_X;
matrix[N_long,p_X] X_long_scale;//treatment on EFA

// for survival data
matrix[I,p_X_intercept] X_intercept_unscale;//treatment on EFA
matrix[I,p_X_slope] X_slope_unscale;//treatment on EFA;. ~trt.group only
int<lower=0> p_Z;
matrix<lower=0>[I,p_Z] Z; //treatment on survival
real<lower=0,upper=71>ttdeath[I];
int<lower=0> n_time_interval;
vector<lower=0,upper=71>[n_time_interval+1]time_spec;
vector<lower=0,upper=1>[I] death;
matrix<lower=0>[I,n_time_interval]zeros;
int<lower=1,upper=n_time_interval>index_interval[I];
}
parameters{
//for longitudinal data
vector[p_X] fix_eff_scale;//fixed effects for intercept
real<lower=0> sigma; // SD of error measurement
cholesky_factor_corr[2] L_Omega; // prior correlation
vector<lower=0,upper=pi()/2>[2] tau_unif;
//vector<lower=0>[2] tau; // prior scale
matrix[2,I] z;
// for survival data
vector[p_Z] beta;//fixed effects for survival
real<lower=0>lambda[n_time_interval]; // piecewise hazard rate
real eta;// trajectory parameter
real<lower=0> sigma_lambda;
}
transformed parameters {
// for longitudinal data
vector[p_X_slope] b_fix_unscale;//original fixed effects for slope
vector[p_X_intercept] a_fix_unscale;//original fixed effects for intercept
vector[N_long]fit_X_long_scale;
vector[I] a_unscale;// estimated intercept
vector[I] b_unscale;// estimated slope


matrix[I,2] U_raw; // patient random effects
matrix[I,2] U_raw_unscale; // patient random effects
// for survival data
vector[I] beta_hat;
real test;
vector<lower=0>[2] tau; // prior scale for random effects
for (k in 1:2) tau[k] = 2.5 * tan(tau_unif[k]);


test=sum((fix_eff_scale[2:p_X].*mean_X[2:p_X])./sd_X[2:p_X]);
a_fix_unscale[1]=fix_eff_scale[1]-sum((fix_eff_scale[2:p_X].*mean_X[2:p_X])./sd_X[2:p_X]);
a_fix_unscale[2:p_X_intercept]=fix_eff_scale[2:p_X_intercept]./sd_X[2:p_X_intercept];
b_fix_unscale=(fix_eff_scale[(p_X_intercept+1):p_X])./sd_X[(p_X_intercept+1):p_X];


U_raw = (diag_pre_multiply(tau,L_Omega) * z)';
for(i in 1:I){
U_raw_unscale[i,1]= U_raw[i,1]-(U_raw[i,2])*mean_X[(p_X_intercept+1)]/sd_X[(p_X_intercept+1)];
}
U_raw_unscale[,2] = U_raw[,2]/sd_X[(p_X_intercept+1)];
// compute individual intercept
fit_X_long_scale=X_long_scale*fix_eff_scale;
a_unscale=X_intercept_unscale*a_fix_unscale+U_raw_unscale[,1];// contains only random effects.
// // compute individual slope
for(i in 1:I){
b_unscale[i]=X_slope_unscale[i,]*b_fix_unscale+U_raw_unscale[i,2];
}
//for survival data
beta_hat=Z*beta;
}
model{
vector[N_long] mu;
vector[I] H;//cummulative hazard function;
vector[I] LL;//log density function
matrix[I,n_time_interval] integral_ht;// cummulative hazard function
// Likelihood for longitudinal component
// Set all priors for all parameters of longitudinal component
fix_eff_scale~normal(0,10);
to_vector(z) ~ normal(0,1);
tau_unif ~ uniform(0,pi()/2);
L_Omega ~ lkj_corr_cholesky(2);
for (k in 1:N_long){
mu[k]=fit_X_long_scale[k]+U_raw[patid[k],1]+(U_raw[patid[k],2])*time_scale[k];
if(y2_censInd[k]==0){
log10fc_obs[k] ~ normal(mu[k],sigma);
}else{
target +=normal_lcdf(C|mu[k],sigma);
}
}
//Likelihood for survival component
//Compute the cumulative hazard function from 0 to ttdeath.
integral_ht=zeros;
for(i in 1:I){
integral_ht[i,index_interval[i]] = lambda[index_interval[i]]*exp(eta*a_unscale[i]+beta_hat[i])*(exp((eta*b_unscale[i])*ttdeath[i])-exp((eta*b_unscale[i])*time_spec[index_interval[i]]))/(eta*b_unscale[i]);
for(j in 1:(index_interval[i]-1)){
integral_ht[i,j] = lambda[j]*exp(eta*a_unscale[i]+beta_hat[i])*(exp((eta*b_unscale[i])*time_spec[j+1])-exp((eta*b_unscale[i])*time_spec[j]))/(eta*b_unscale[i]);
}
//Integrated hazard for individual i from 0 to survival time t.surv[i]
H[i]=sum(integral_ht[i,]);// cummulative hazard function
//Survival function
LL[i]=(log(lambda[index_interval[i]])+eta*(a_unscale[i]+b_unscale[i]*ttdeath[i])+beta_hat[i])*death[i]-H[i];
}
target += sum(LL);
//Set all priors for all parameters of survival component
beta ~ normal(0,10);
if(n_time_interval>2){
lambda[1] ~ lognormal(0,5);
}else{
lambda[1] ~ normal(0,5);
}
for(i in 2:n_time_interval){
lambda[i]~lognormal(lambda[i-1],sigma_lambda);
}
sigma_lambda~cauchy(0,2.5);
eta ~ normal(0,10);
}
generated quantities {
vector[p_X_slope] b_fix_unscale_true;
b_fix_unscale_true[1]=b_fix_unscale[1];
for(i in 2:p_X_slope){
b_fix_unscale_true[i]=b_fix_unscale[1]+b_fix_unscale[i];

Section 3. The difference in QTc between two study arms over the first 2 weeks of study drug administration

Study day	Difference of QTC between study arms before drug using (95% CI)	Difference of QTC between study arms 2 hr after drug using (95% CI)
0	0.00 (0.00, 0.00)	0.00 (0.00, 0.00)
1	3.73 (-0.29, 7.74)	7.44 (3.45, 11.44)
2	7.63 (0.09, 15.18)	14.51 (6.99, 22.02)
3	11.91 (1.75, 22.06)	20.8 (10.69, 30.92)
4	16.73 (5.2, 28.25)	25.96 (14.47, 37.45)
5	22.13 (10.28, 33.97)	29.68 (17.85, 41.5)
6	27.55 (15.32, 39.78)	32.05 (19.82, 44.27)
7	32.29 (18.96, 45.62)	33.24 (19.92, 46.57)
8	35.63 (20.85, 50.42)	33.44 (18.67, 48.21)
9	37.07 (21.09, 53.04)	32.82 (16.86, 48.77)
10	36.82 (19.81, 53.83)	31.54 (14.55, 48.53)
11	35.32 (16.92, 53.72)	29.77 (11.39, 48.15)
12	32.97 (12.41, 53.54)	27.67 (7.13, 48.21)
13	30.21 (6.65, 53.77)	25.41 (1.89, 48.93)

Appendix 1—figure 1

Download asset Open asset

The clinical trial has been conducted in Vietnam under the Ministry of Health and local Ethical Committee approvals. Requests to share the clinical data underlying the trial have to be acknowledged by the local Ethical Committee (and therefore we cannot hand over the data repository or management to an external party). The original de-identified clinical data underlying the study are available by emailing the OUCRU Data Access Committee at DAC@oucru.org or ekestelyn@oucru.org (Head of the Clinical Trials Unit and Data Access Committee Chair). The review procedures (the data sharing policy and the data request form) are available on the OUCRU website at http://www.oucru.org/data-sharing/. The code for the study analysis is freely available at https://doi.org/10.5287/bodleian:XmeOzdR8z.

1. 1. Ngan NTT
   2. Thanh HoangLe N
   3. Vi NN
   4. Van NTT
   5. Mai NTH
   6. Anh DV
   7. Trieu PH
   8. Lan NPH
   9. Phu NH
   10. Chau NV
   11. Lalloo DG
   12. Hope W
   13. Beardsley J
   14. White NJ
   15. Geskus R
   16. Thwaites GE
   17. Krysan D
   18. Tai LTH
   19. Kestelyn E
   20. Binh TQ
   21. Hung LQ
   22. Tung NLN
   23. Day JN

   (2021) Oxford University Clinical Research Unit

   ID 28CN. 28CN: An open label randomized controlled trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis.

   http://www.oucru.org/
2. 1. Ngan NTT
   2. Thanh HoangLe N
   3. Vi NN
   4. Van NTT
   5. Mai NTH
   6. Anh DV
   7. Trieu PH
   8. Lan NPH
   9. Phu NH
   10. Chau NV
   11. Lalloo DG
   12. Hope W
   13. Beardsley J
   14. White NJ
   15. Geskus R
   16. Thwaites GE
   17. Krysan D
   18. Tai LTH
   19. Kestelyn E
   20. Binh TQ
   21. Hung LQ
   22. Tung NLN
   23. Day JN

   (2021) Oxford University Research Archive

   Statistical Analysis Code: An open label randomized controlled trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis.

   https://doi.org/10.5287/bodleian:XmeOzdR8z

1. 1. Ashton PM
   2. Thanh LT
   3. Trieu PH
   4. Van Anh D
   5. Trinh NM
   6. Beardsley J
   7. Kibengo F
   8. Chierakul W
   9. Dance DAB
   10. Rattanavong S
   11. Davong V
   12. Hung LQ
   13. Chau NVV
   14. Tung NLN
   15. Chan AK
   16. Thwaites GE
   17. Lalloo DG
   18. Anscombe C
   19. Nhat LTH
   20. Perfect J
   21. Dougan G
   22. Baker S
   23. Harris S
   24. Day JN

   (2019) Three phylogenetic groups have driven the recent population expansion of cryptococcus neoformans

   Nature Communications 10:2035.

   https://doi.org/10.1038/s41467-019-10092-5

   • PubMed
   • Google Scholar
2. 1. Asp ML
   2. Martindale JJ
   3. Metzger JM

   (2013) Direct, differential effects of tamoxifen, 4-hydroxytamoxifen, and raloxifene on cardiac myocyte contractility and calcium handling

   PLOS ONE 8:e78768.

   https://doi.org/10.1371/journal.pone.0078768

   • PubMed
   • Google Scholar
3. 1. Beardsley J
   2. Wolbers M
   3. Kibengo FM
   4. Ggayi AB
   5. Kamali A
   6. Cuc NT
   7. Binh TQ
   8. Chau NV
   9. Farrar J
   10. Merson L
   11. Phuong L
   12. Thwaites G
   13. Van Kinh N
   14. Thuy PT
   15. Chierakul W
   16. Siriboon S
   17. Thiansukhon E
   18. Onsanit S
   19. Supphamongkholchaikul W
   20. Chan AK
   21. Heyderman R
   22. Mwinjiwa E
   23. van Oosterhout JJ
   24. Imran D
   25. Basri H
   26. Mayxay M
   27. Dance D
   28. Phimmasone P
   29. Rattanavong S
   30. Lalloo DG
   31. Day JN
   32. CryptoDex Investigators

   (2016) Adjunctive dexamethasone in HIV-Associated cryptococcal meningitis

   New England Journal of Medicine 374:542–554.

   https://doi.org/10.1056/NEJMoa1509024

   • PubMed
   • Google Scholar
4. 1. Bicanic T
   2. Muzoora C
   3. Brouwer AE
   4. Meintjes G
   5. Longley N
   6. Taseera K
   7. Rebe K
   8. Loyse A
   9. Jarvis J
   10. Bekker LG
   11. Wood R
   12. Limmathurotsakul D
   13. Chierakul W
   14. Stepniewska K
   15. White NJ
   16. Jaffar S
   17. Harrison TS

   (2009) Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients

   Clinical Infectious Diseases 49:702–709.

   https://doi.org/10.1086/604716

   • PubMed
   • Google Scholar
5. 1. Brouwer AE
   2. Rajanuwong A
   3. Chierakul W
   4. Griffin GE
   5. Larsen RA
   6. White NJ
   7. Harrison TS

   (2004) Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial

   The Lancet 363:1764–1767.

   https://doi.org/10.1016/S0140-6736(04)16301-0

   • PubMed
   • Google Scholar
6. 1. Butts A
   2. Koselny K
   3. Chabrier-Roselló Y
   4. Semighini CP
   5. Brown JC
   6. Wang X
   7. Annadurai S
   8. DiDone L
   9. Tabroff J
   10. Childers WE
   11. Abou-Gharbia M
   12. Wellington M
   13. Cardenas ME
   14. Madhani HD
   15. Heitman J
   16. Krysan DJ

   (2014) Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo

   mBio 5:e00765-13.

   https://doi.org/10.1128/mBio.00765-13

   • PubMed
   • Google Scholar
7. 1. Campbell I

   (2007) And Fisher-Irwin tests of two-by-two tables with small sample recommendations

   Statistics in Medicine 26:3661–3675.

   https://doi.org/10.1002/sim.2832

   • PubMed
   • Google Scholar
8. 1. Chau TT
   2. Mai NH
   3. Phu NH
   4. Nghia HD
   5. Chuong LV
   6. Sinh DX
   7. Duong VA
   8. Diep PT
   9. Campbell JI
   10. Baker S
   11. Hien TT
   12. Lalloo DG
   13. Farrar JJ
   14. Day JN

   (2010) A prospective descriptive study of cryptococcal meningitis in HIV uninfected patients in Vietnam - high prevalence of Cryptococcus neoformans var grubii in the absence of underlying disease

   BMC Infectious Diseases 10:199.

   https://doi.org/10.1186/1471-2334-10-199

   • PubMed
   • Google Scholar
9. Report

   1. CLSI

   (2002)

   M27-A2 Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts

   CLSI.

   • Google Scholar
10. 1. Day JN
    2. Hoang TN
    3. Duong AV
    4. Hong CT
    5. Diep PT
    6. Campbell JI
    7. Sieu TP
    8. Hien TT
    9. Bui T
    10. Boni MF
    11. Lalloo DG
    12. Carter D
    13. Baker S
    14. Farrar JJ

    (2011) Most cases of cryptococcal meningitis in HIV-uninfected patients in Vietnam are due to a distinct amplified fragment length polymorphism-defined cluster of Cryptococcus neoformans var. grubii VN1

    Journal of Clinical Microbiology 49:658–664.

    https://doi.org/10.1128/JCM.01985-10

    • PubMed
    • Google Scholar
11. 1. Day JN
    2. Chau TTH
    3. Wolbers M
    4. Mai PP
    5. Dung NT
    6. Mai NH
    7. Phu NH
    8. Nghia HD
    9. Phong ND
    10. Thai CQ
    11. Thai LH
    12. Chuong LV
    13. Sinh DX
    14. Duong VA
    15. Hoang TN
    16. Diep PT
    17. Campbell JI
    18. Sieu TPM
    19. Baker SG
    20. Chau NVV
    21. Hien TT
    22. Lalloo DG
    23. Farrar JJ

    (2013) Combination antifungal therapy for cryptococcal meningitis

    New England Journal of Medicine 368:1291–1302.

    https://doi.org/10.1056/NEJMoa1110404

    • PubMed
    • Google Scholar
12. 1. Day JN
    2. Qihui S
    3. Thanh LT
    4. Trieu PH
    5. Van AD
    6. Thu NH
    7. Chau TTH
    8. Lan NPH
    9. Chau NVV
    10. Ashton PM
    11. Thwaites GE
    12. Boni MF
    13. Wolbers M
    14. Nagarajan N
    15. Tan PBO
    16. Baker S

    (2017) Comparative genomics of Cryptococcus neoformans var. grubii associated with meningitis in HIV infected and uninfected patients in Vietnam

    PLOS Neglected Tropical Diseases 11:e0005628.

    https://doi.org/10.1371/journal.pntd.0005628

    • PubMed
    • Google Scholar
13. 1. Dolan K
    2. Montgomery S
    3. Buchheit B
    4. DiDone L
    5. Wellington M
    6. Krysan DJ

    (2009) Antifungal activity of tamoxifen: in vitro and in vivo activities and mechanistic characterization

    Antimicrobial Agents and Chemotherapy 53:3337–3346.

    https://doi.org/10.1128/AAC.01564-08

    • Google Scholar
14. 1. Fok E
    2. Kassai T

    (1998) Toxocara canis infection in the paratenic host: a study on the chemosusceptibility of the somatic larvae in mice

    Veterinary Parasitology 74:243–259.

    https://doi.org/10.1016/s0304-4017(97)00086-1

    • PubMed
    • Google Scholar
15. 1. Franzot SP
    2. Hamdan JS
    3. Currie BP
    4. Casadevall A

    (1997) Molecular epidemiology of Cryptococcus neoformans in Brazil and the United States: evidence for both local genetic differences and a global clonal population structure

    Journal of Clinical Microbiology 35:2243–2251.

    https://doi.org/10.1128/jcm.35.9.2243-2251.1997

    • PubMed
    • Google Scholar
16. 1. Grouthier V
    2. Lebrun-Vignes B
    3. Glazer AM
    4. Touraine P
    5. Funck-Brentano C
    6. Pariente A
    7. Courtillot C
    8. Bachelot A
    9. Roden DM
    10. Moslehi JJ
    11. Salem JE

    (2018) Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors

    Heart 104:1859–1863.

    https://doi.org/10.1136/heartjnl-2017-312934

    • PubMed
    • Google Scholar
17. 1. Hai TP
    2. Van AD
    3. Ngan NTT
    4. Nhat LTH
    5. Lan NPH
    6. Vinh Chau NV
    7. Thwaites GE
    8. Krysan D
    9. Day JN

    (2019) The combination of tamoxifen with amphotericin B, but not with fluconazole, has synergistic activity against the majority of clinical isolates of Cryptococcus neoformans

    Mycoses 62:818–825.

    https://doi.org/10.1111/myc.12955

    • PubMed
    • Google Scholar
18. 1. Han S
    2. Zhang Y
    3. Chen Q
    4. Duan Y
    5. Zheng T
    6. Hu X
    7. Zhang Z
    8. Zhang L

    (2011) Fluconazole inhibits hERG K(+) channel by direct block and disruption of protein trafficking

    European Journal of Pharmacology 650:138–144.

    https://doi.org/10.1016/j.ejphar.2010.10.010

    • PubMed
    • Google Scholar
19. 1. He J
    2. Kargacin ME
    3. Kargacin GJ
    4. Ward CA

    (2003) Tamoxifen inhibits na+ and K+ currents in rat ventricular myocytes

    American Journal of Physiology. Heart and Circulatory Physiology 285:H661–H668.

    https://doi.org/10.1152/ajpheart.00686.2002

    • PubMed
    • Google Scholar
20. 1. Khoo SH
    2. Bond J
    3. Denning DW

    (1994) Administering amphotericin B—a practical approach

    Journal of Antimicrobial Chemotherapy 33:203–213.

    https://doi.org/10.1093/jac/33.2.203

    • Google Scholar
21. 1. Lien EA
    2. Solheim E
    3. Ueland PM

    (1991a)

    Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment

    Cancer Research 51:4837–4844.

    • PubMed
    • Google Scholar
22. 1. Lien EA
    2. Wester K
    3. Lønning PE
    4. Solheim E
    5. Ueland PM

    (1991b) Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast Cancer patients

    British Journal of Cancer 63:641–645.

    https://doi.org/10.1038/bjc.1991.147

    • PubMed
    • Google Scholar
23. 1. Liu XK
    2. Katchman A
    3. Ebert SN
    4. Woosley RL

    (1998)

    The antiestrogen tamoxifen blocks the delayed rectifier potassium current, IKr, in rabbit ventricular myocytes

    The Journal of Pharmacology and Experimental Therapeutics 287:877–883.

    • PubMed
    • Google Scholar
24. 1. Merry M
    2. Boulware DR

    (2016) Cryptococcal meningitis treatment strategies affected by the explosive cost of flucytosine in the United States: a Cost-effectiveness analysis

    Clinical Infectious Diseases 62:1564–1568.

    https://doi.org/10.1093/cid/ciw151

    • PubMed
    • Google Scholar
25. 1. Molloy SF
    2. Kanyama C
    3. Heyderman RS
    4. Loyse A
    5. Kouanfack C
    6. Chanda D
    7. Mfinanga S
    8. Temfack E
    9. Lakhi S
    10. Lesikari S
    11. Chan AK
    12. Stone N
    13. Kalata N
    14. Karunaharan N
    15. Gaskell K
    16. Peirse M
    17. Ellis J
    18. Chawinga C
    19. Lontsi S
    20. Ndong JG
    21. Bright P
    22. Lupiya D
    23. Chen T
    24. Bradley J
    25. Adams J
    26. van der Horst C
    27. van Oosterhout JJ
    28. Sini V
    29. Mapoure YN
    30. Mwaba P
    31. Bicanic T
    32. Lalloo DG
    33. Wang D
    34. Hosseinipour MC
    35. Lortholary O
    36. Jaffar S
    37. Harrison TS
    38. ACTA Trial Study Team

    (2018) Antifungal combinations for treatment of cryptococcal meningitis in africa

    New England Journal of Medicine 378:1004–1017.

    https://doi.org/10.1056/NEJMoa1710922

    • PubMed
    • Google Scholar
26. 1. Ngan NTT
    2. Mai NTH
    3. Tung NLN
    4. Lan NPH
    5. Tai LTH
    6. Phu NH
    7. Chau NVV
    8. Binh TQ
    9. Hung LQ
    10. Beardsley J
    11. White N
    12. Lalloo D
    13. Krysan D
    14. Hope W
    15. Geskus R
    16. Wolbers M
    17. Nhat LTH
    18. Thwaites G
    19. Kestelyn E
    20. Day J

    (2019) A randomized open label trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis

    Wellcome Open Research 4:8.

    https://doi.org/10.12688/wellcomeopenres.15010.1

    • PubMed
    • Google Scholar
27. 1. O'Connor L
    2. Van Anh D
    3. Chau TTH
    4. Chau NVV
    5. Huong LNP
    6. Wolbers M
    7. Day JN

    (2020) Antifungal susceptibility does not correlate with fungal clearance or survival in AIDS-associated cryptococcal meningitis

    Clinical Infectious Diseases 1:ciaa1544.

    https://doi.org/10.1093/cid/ciaa1544

    • PubMed
    • Google Scholar
28. 1. Pan G
    2. Zhou T
    3. Radding W
    4. Saag MS
    5. Mountz JD
    6. McDonald JM

    (1998) Calmodulin antagonists inhibit apoptosis of CD4+ T-cells from patients with AIDS

    Immunopharmacology 40:91–103.

    https://doi.org/10.1016/S0162-3109(98)00018-6

    • PubMed
    • Google Scholar
29. Software

    1. R Development Core Team

    (2018) R: A language and environment for statistical computing

    R Foundation for Statistical Computing, Vienna, Austria.

    https://www.R-project.org/
30. 1. Rajasingham R
    2. Smith RM
    3. Park BJ
    4. Jarvis JN
    5. Govender NP
    6. Chiller TM
    7. Denning DW
    8. Loyse A
    9. Boulware DR

    (2017) Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis

    The Lancet Infectious Diseases 17:873–881.

    https://doi.org/10.1016/S1473-3099(17)30243-8

    • PubMed
    • Google Scholar
31. 1. Rhein J
    2. Morawski BM
    3. Hullsiek KH
    4. Nabeta HW
    5. Kiggundu R
    6. Tugume L
    7. Musubire A
    8. Akampurira A
    9. Smith KD
    10. Alhadab A
    11. Williams DA
    12. Abassi M
    13. Bahr NC
    14. Velamakanni SS
    15. Fisher J
    16. Nielsen K
    17. Meya DB
    18. Boulware DR
    19. ASTRO-CM Study Team

    (2016) Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study

    The Lancet Infectious Diseases 16:809–818.

    https://doi.org/10.1016/S1473-3099(16)00074-8

    • PubMed
    • Google Scholar
32. 1. Rhein J
    2. Huppler Hullsiek K
    3. Tugume L
    4. Nuwagira E
    5. Mpoza E
    6. Evans EE
    7. Kiggundu R
    8. Pastick KA
    9. Ssebambulidde K
    10. Akampurira A
    11. Williams DA
    12. Bangdiwala AS
    13. Abassi M
    14. Musubire AK
    15. Nicol MR
    16. Muzoora C
    17. Meya DB
    18. Boulware DR
    19. ASTRO-CM team

    (2019) Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial

    The Lancet Infectious Diseases 19:843–851.

    https://doi.org/10.1016/S1473-3099(19)30127-6

    • PubMed
    • Google Scholar
33. 1. Schwarz P
    2. Dromer F
    3. Lortholary O
    4. Dannaoui E

    (2003) In vitro interaction of flucytosine with conventional and new antifungals against cryptococcus neoformans clinical isolates

    Antimicrobial Agents and Chemotherapy 47:3361–3364.

    https://doi.org/10.1128/AAC.47.10.3361-3364.2003

    • PubMed
    • Google Scholar
34. Software

    1. Stan Development Team

    (2019) Users Guide and Reference Manual, version 2.19.2

    Stan Modeling Language.

    https://mc-stan.org
35. 1. Truong M
    2. Monahan LG
    3. Carter DA
    4. Charles IG

    (2018) Repurposing drugs to fast-track therapeutic agents for the treatment of cryptococcosis

    PeerJ 6:e4761.

    https://doi.org/10.7717/peerj.4761

    • PubMed
    • Google Scholar
36. 1. Villanueva-Lozano H
    2. Treviño-Rangel RJ
    3. González GM
    4. Hernández-Rodríguez PA
    5. Camacho-Ortiz A
    6. Castillo-Reyna L
    7. Galindo-Alvarado SG
    8. Martínez-Reséndez MF

    (2018) Clinical evaluation of the antifungal effect of sertraline in the treatment of cryptococcal meningitis in HIV patients: a single Mexican center experience

    Infection 46:25–30.

    https://doi.org/10.1007/s15010-017-1059-3

    • PubMed
    • Google Scholar
37. Conference

    1. World Health Organization

    (2018)

    Guidelines on the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children

    Supplement to the 2016 Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection.

    • Google Scholar
38. 1. Zhai B
    2. Wu C
    3. Wang L
    4. Sachs MS
    5. Lin X

    (2012) The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections

    Antimicrobial Agents and Chemotherapy 56:3758–3766.

    https://doi.org/10.1128/AAC.00212-12

    • PubMed
    • Google Scholar

Acceptance summary:

This paper will be of particular interest to those in the fields of infectious diseases, HIV, medical mycology, and central nervous system infections; also those interested in drug re-purposing. The main findings, that Tamoxifen, given in addition to the usual antifungal drugs, does not accelerate the rate of clearance of cryptococcal infection from the cerebrospinal fluid in patients with cryptococcal meningitis, and is associated with an increased risk of Cardiac QT prolongation, are well supported by the data. Such small randomised phase II studies are a very useful first clinical step, in order to select only the most promising novel treatments for testing in larger trials.

Decision letter after peer review:

Thank you for submitting your article "An open label randomized controlled trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis" for consideration by eLife. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Jos van der Meer as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Thomas S. Harrison (Reviewer #1).

The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.

Essential revisions:

1) It is slightly confusing as to the different assessments of QT interval. There were no cut offs for grade 3 and 4 QT prolongation as reported in table 4 – could these be added in methods? – a different (I assume) classification of "mildly prolonged" and "prolonged" was found in the statistical analysis plan.

2) In Figure 3 could an average be given for the increase in QT interval when this is maximal? – the reader can read off the graph but I think it would be useful to have the number in manuscript given in the legend.

3) It is surprising that no apparent effect of fluconazole was seen on QT – wasn’t this hard to assess given all participants received the same fluconazole dose?

4) Perhaps in the discussion, it could be mentioned that progress is now being made with flucytosine manufacture, pricing, and access – with generic manufacture now started, and costs reduced to US$70 per 100 x 500 mg tablets.

5) The rate of synergy in the tested isolates was less then in previous reports. Can the authors explain this observation? Is it possible that other cryptococcal genotypes show a higher rate of synergistic interactions? If so should the trial be repeated in areas with a higher rate of synergistic interactions? The previous in vitro interaction study was performed with a similar randomly selected set of Vietnamese isolates so this is perhaps unlikely.

6) Were antagonistic interaction observed? Can the authors present the results of the in vitro interaction study show interactions in a supplemental table.

7) Line 196 " The secondary outcomes are summarized in Table 3". However the secondary: serious adverse effects, were not included in this table.

8) The study was not powered to detect differences in rare serious adverse effects. The absolute number of adverse effects are higher in the tamoxifen arm but most are not significantly different. The authors should discuss this lack of power to detect SE in the discussion.Reviewer #1:

The paper describes an open label randomised phase II trial of the treatment of cryptococcal meningitis in Vietnam. 2 weeks of high dose (300mg/day) Tamoxifen was added, or not, to the usual initial antifungal treatment in Vietnam of 2 weeks of amphotericin B deoxycholate plus fluconazole, after which all participants received the usual follow-on treatment with fluconazole alone.

Rate of clearance of infection or early fungicidal activity (EFA) was the same with and without tamoxifen, and tamoxifen was associated with increased QT interval. The authors conclude that there is no justification for a larger study of tamoxifen in this condition.

The study was performed and analysed to a very high standard, and the report is clearly written. The conclusions appear robust – no trend is seen in the EFA, and an effect of tamoxifen on cardiac conduction supported by an increase in the mean QT interval over the first 14 days, as well as by an increased number of participants reaching thresholds levels.

EFA is not a perfect surrogate marker of outcome in cryptococcal meningitis. It cannot capture issues of toxicity (hence the need to assess this separately). And the shape of the association of EFA and outcome may not be linear, such that there may be a threshold above which further increases in EFA do not translate into better outcome. Nevertheless, the authors conclude, and I concur, that such randomised phase II EFA studies are a very useful method for helping select only the most promising novel agents or regimens for testing in larger phase 3 trials.Reviewer #2:

The authors describe the results of an open label RCT that evaluates the use of tamoxifen to improve the treatment of cryptococcal meningitis. Using a smart design with a low number of patients, the authors did not find a significant difference in their primary endpoint and conclude that addition of tamoxifen is unlikely to be of clinical benefit.

Overall the manuscript is well written with appropriate use of tables and figures. The introduction is well ordered and gives strong arguments about why tamoxifen is evaluated. The authors describe the beneficial in vitro effects of tamoxifen in combination with other antifungal agents and favorable and clinical achievable pk/pd. Furthermore, the authors give strong arguments for their study design and use of the primary outcome which is defined as Early Fungicidal Activity. The results are clearly presented and the adverse events are well described.

The absolute number of adverse effects are higher in the tamoxifen arm but most are not significantly different. The trial design with a low number of patients is not powered to find differences in adverse events. This study shows that promising preclinical data should first be evaluated using well designed clinical trials.

Essential revisions:

1) It is slightly confusing as to the different assessments of QT interval. There were no cut offs for grade 3 and 4 QT prolongation as reported in table 4 – could these be added in methods? – a different (I assume) classification of "mildly prolonged" and "prolonged" was found in the statistical analysis plan.

Prolonged QTc was classified according to the grading system of the NIH Common

Terminology Criteria for Adverse Events. We have clarified this in the methods lines 125 to 128.

2) In Figure 3 could an average be given for the increase in QT interval when this is maximal? – the reader can read off the graph but I think it would be useful to have the number in manuscript given in the legend.

We have added this information to the legend of Figure 3 (lines 358-362).

3) It is surprising that no apparent effect of fluconazole was seen on QT – wasn’t this hard to assess given all participants received the same fluconazole dose?

The reviewer is correct that all patients, in both treatment arms, received fluconazole. Therefore we can only with rigor ascribe changes in QTc to the use of tamoxifen. We did not detect statistically significant changes in QTc over the first 2 weeks of treatment in patients in the control arm although to the naked eye the curves in figure 3 perhaps seem to rise slightly over the 2 week period. Any change that might occur in QTc seen in the control arm could be due to a number of causes such as accumulating fluconazole, natural disease progression, changes in electrolytes or other treatment (eg amphotericin). However, the notable finding in the control arm is that there was no measurable change in QTc despite the use of fluconazole at robust doses (800mg/day). Of note, the literature describing fluconazole-induced QTc prolongation has been comprised of mostly observational studies and/or case reports. The average time between starting an azole antifungal drug and the development of QTc prolongation is unknown although the appearance of Torsade de Pointes has been reported between 4-6 days (Salem et al., 2017, PMID 29644223). Our data likely reflects the most systematic measurement of QTc with 2 weeks of relatively high dose fluconazole and should provide reassurance about the safety of this drug at these doses.

4) Perhaps in the discussion, it could be mentioned that progress is now being made with flucytosine manufacture, pricing, and access – with generic manufacture now started, and costs reduced to US$70 per 100 x 500 mg tablets.

We have added this information to the discussion (lines 278-282).

5) The rate of synergy in the tested isolates was less then in previous reports. Can the authors explain this observation? Is it possible that other cryptococcal genotypes show a higher rate of synergistic interactions? If so should the trial be repeated in areas with a higher rate of synergistic interactions? The previous in vitro interaction study was performed with a similar randomly selected set of Vietnamese isolates so this is perhaps unlikely.

We have also been puzzled by the lack of synergy seen in isolates from this study. As the reviewer states our previous work included randomly selected clinical isolates, and these included the 3 dominant genotypes causing disease in Vietnam, including VNIa5 (dominant in China), VNIa4 (dominant in western southeast Asia Laos and Thailand) and VNIa93, common in east Africa. We found no association between susceptibility and genotype and therefore don’t think this is likely to explain the findings here. Rather, as we state in lines 276 – 278, we believe we need to develop better tools for determining drug susceptibility in vitro and for screening potential therapeutic compounds.

6) Were antagonistic interaction observed? Can the authors present the results of the in vitro interaction study show interactions in a supplemental table.

We found no evidence of antagonistic interactions observed in susceptibility testing. We have added Section 5 – “Results of drug interactions from two-dimensional

chequerboard testing of tamoxifen in combination with either amphotericin, fluconazole” to the Supplementary materials Page 80.

7) Line 196 " The secondary outcomes are summarized in Table 3". However the secondary: serious adverse effects, were not included in this table.

We have clarified the secondary outcomes reported in Table 3 (death, disabilities, and change in CD4 count) in line 197. Grade 3 and 4 adverse events are reported in Table 4.

8) The study was not powered to detect differences in rare serious adverse effects. The absolute number of adverse effects are higher in the tamoxifen arm but most are not significantly different. The authors should discuss this lack of power to detect SE in the discussion.

We agree with the reviewer – the study was powered to show differences in the rate of sterilisation of cerebrospinal fluid of a magnitude that we believed might be likely to

confer a survival benefit and thus justify a larger trial powered to a survival endpoint. We found no statistically significant difference in number of grade 3 or 4 adverse events between study arms (Table 4) other than prolonged QTc which was consistent with the additional analysis using a linear mixed effect model (Figure 3). However since there is no justification for progression to a larger trial, this is something of a moot point. We have added the sentence ‘Our study was powered to detect a difference in the rate of clearance of yeast from CSF and therefore may have lacked power to detect differences in rates of rarer adverse events’ (lines 246 to 247).

Author details

1. Nguyen Thi Thuy Ngan

   1. Department of Tropical Medicine, Cho Ray Hospital, Ho Chi Minh City, Viet Nam
   2. Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam

   Contribution

   Conceptualization, Formal analysis, Investigation, Methodology, Writing - original draft, Project administration

   Competing interests

   No competing interests declared

2. Nhat Thanh Hoang Le

   Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam

   Contribution

   Data curation, Software, Formal analysis, Validation, Visualization, Methodology, Writing - original draft

   Competing interests

   No competing interests declared

3. Nguyen Ngo Vi Vi

   Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam

   Contribution

   Investigation, Methodology, Writing - review and editing

   Competing interests

   No competing interests declared

4. Ninh Thi Thanh Van

   Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam

   Contribution

   Validation, Investigation, Project administration

   Competing interests

   No competing interests declared

5. Nguyen Thi Hoang Mai

   Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam

   Contribution

   Data curation, Investigation, Methodology, Writing - review and editing

   Competing interests

   No competing interests declared

6. Duong Van Anh

   Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam

   Contribution

   Conceptualization, Data curation, Investigation, Methodology, Writing - review and editing

   Competing interests

   No competing interests declared

7. Phan Hai Trieu

   Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam

   Contribution

   Investigation, Methodology, Writing - review and editing

   Competing interests

   No competing interests declared

8. Nguyen Phu Huong Lan

   The Hospital for Tropical Diseases, Ho Chi Minh City, Viet Nam

   Contribution

   Investigation, Methodology, Writing - review and editing

   Competing interests

   No competing interests declared

9. Nguyen Hoan Phu

   Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam

   Contribution

   Investigation, Methodology, Writing - review and editing

   Competing interests

   No competing interests declared

10. Nguyen Van Vinh Chau

    The Hospital for Tropical Diseases, Ho Chi Minh City, Viet Nam

    Contribution

    Resources, Investigation, Methodology, Writing - review and editing

    Competing interests

    No competing interests declared

11. David G Lalloo

    Liverpool School of Tropical Medicine, Liverpool, United Kingdom

    Contribution

    Validation, Writing - review and editing

    Competing interests

    No competing interests declared

12. William Hope

    Centre of Excellence in Infectious Disease Research, Institute of Translational Medicine, Liverpool University, Liverpool, United Kingdom

    Contribution

    Investigation, Methodology, Writing - review and editing

    Competing interests

    No competing interests declared

13. Justin Beardsley

    1. The University of Sydney, Marie Bashir Institute, NSW, Camperdown, Australia
    2. Westmead Institute for Medical Research, Westmead, Australia

    Contribution

    Investigation, Writing - review and editing

    Competing interests

    No competing interests declared

14. Nicholas J White

    1. Mahidol Oxford Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
    2. Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

    Contribution

    Conceptualization, Writing - review and editing

    Competing interests

    No competing interests declared

    "This ORCID iD identifies the author of this article:" 0000-0002-1897-1978

15. Ronald Geskus

    1. Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam
    2. Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

    Contribution

    Formal analysis, Writing - review and editing

    Competing interests

    No competing interests declared

16. Guy E Thwaites

    1. Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam
    2. Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

    Contribution

    Resources, Writing - review and editing

    Competing interests

    No competing interests declared

    "This ORCID iD identifies the author of this article:" 0000-0002-2858-2087

17. Damian Krysan

    Department of Paediatrics and Microbiology/Immunology, Carver College of Medicine, University of Iowa, Iowa City, United States

    Contribution

    Conceptualization, Writing - review and editing

    Competing interests

    No competing interests declared

18. Luong Thi Hue Tai

    The Hospital for Tropical Diseases, Ho Chi Minh City, Viet Nam

    Contribution

    Investigation, Writing - review and editing

    Competing interests

    No competing interests declared

19. Evelyne Kestelyn

    1. Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam
    2. Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

    Contribution

    Resources, Data curation, Supervision, Validation, Methodology, Project administration, Writing - review and editing

    Competing interests

    No competing interests declared

    "This ORCID iD identifies the author of this article:" 0000-0002-5728-0918

20. Tran Quang Binh

    Department of Tropical Medicine, Cho Ray Hospital, Ho Chi Minh City, Viet Nam

    Contribution

    Supervision, Methodology, Writing - review and editing

    Competing interests

    No competing interests declared

21. Le Quoc Hung

    Department of Tropical Medicine, Cho Ray Hospital, Ho Chi Minh City, Viet Nam

    Contribution

    Supervision, Investigation, Methodology, Writing - review and editing

    Competing interests

    No competing interests declared

22. Nguyen Le Nhu Tung

    The Hospital for Tropical Diseases, Ho Chi Minh City, Viet Nam

    Contribution

    Resources, Investigation, Methodology, Project administration, Writing - review and editing

    Competing interests

    No competing interests declared

23. Jeremy N Day

    1. Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam
    2. Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

    Contribution

    Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing - original draft, Project administration, Writing - review and editing

    For correspondence

    jday@oucru.org

    Competing interests

    No competing interests declared

    "This ORCID iD identifies the author of this article:" 0000-0002-7843-6280

• 1,044

  Page views

• 132

  Downloads

• 10

  Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.